Distinct molecular prognostic markers were identified, with SETD2 mutations linked to poorer outcomes in LCC and ARID1A and PRDM1 mutations impacting RCC. This evidence concerns the gene PRDM1 and leukoencephalopathy with calcifications and cysts.